Review
Nature Reviews Cancer 8, 299-308 (April 2008) | doi:10.1038/nrc2355
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg1, Nicholas P. Restifo1, James C. Yang1, Richard A. Morgan1 About the authors & Mark E. Dudley1
Abstract
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
- View At a Glance
Author affiliations
- Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA.
Correspondence to: Steven A. Rosenberg1 Email: sar@nih.gov
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Immunotherapy Vaccine trials in melanoma?time for reflectionNature Reviews Clinical Oncology News and Views (01 May 2009)
RESEARCH
Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic?ischemic ratsJournal of Cerebral Blood Flow & Metabolism Original Article
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo ? use of the human tyrosinase promoter with human enhancersCancer Gene Therapy Original Article
See all 43 matches for Research